Introduction India is entering an important phase in pharmaceutical manufacturing, with increasing attention on domestic API production, supply chain resilience, advanced manufacturing and global competitiveness. Active Pharmaceutical Ingredients, or APIs, are the key substances responsible for the therapeutic action of medicines. Their availability directly influences the production of finished pharmaceutical formulations. India has traditionally been a major global pharmaceutical manufacturing hub , but dependence on imported APIs, Key Starting Materials (KSMs) and Drug Intermediates (DIs) has highlighted the need for a stronger domestic supply base. In response, the Indian government has introduced several initiatives designed to expand local manufacturing capacity and reduce supply vulnerabilities. As of December 2025, 38 projects covering 28 notified products had been commissioned under the PLI scheme for bulk drugs, creating approximately 56,800 tonnes per year of domestic m...
Introduction India has become one of the world's major pharmaceutical manufacturing and supply destinations. Active Pharmaceutical Ingredients, commonly known as APIs, are essential components of medicines because they provide therapeutic effects. With increasing healthcare demand and changing global sourcing strategies, India's API manufacturing sector is entering a critical phase of development. The industry is being influenced by several factors, including domestic manufacturing initiatives, technological development, supply chain diversification, sustainability and international pharmaceutical demand. India's pharmaceutical exports reached around US$30.47 billion during FY 2024–25, demonstrating the country's continuing importance in the global pharmaceutical market. Growing Focus on Domestic API Manufacturing Reducing dependence on imported pharmaceutical raw materials has become an important objective for India. Government initiatives, including the Production ...